ALBERT

Keywords: QD1-999 ; Q1-390 ; alginate ; n/a ; edema ; Heparin Red ; solid lipid nanoparticles ; Fe3O4·DA-BSA/HA ; dermatan sulfate ; sulfated alginate ; porcine heparin ; theranostics ; low-molecular-weight heparin ; Arixtra® ; biomaterials ; hepcidin ; ovarian cancer ; iron oxide nanoparticles ; heparin-induced thrombocytopenia ; bone morphogenetic protein (BMP) ; hyaluronic acid (HA) ; crude heparin ; platelets ; resistance ; sclerostin ; LMWH ; gremlin ; low molecular weight heparin (LMWH) ; low molecular weight glycosaminoglycans ; human plasma ; single crystal X-ray structure ; iron homeostasis ; noggin ; super paramagnetic iron oxide nanoparticles (SPION) ; manufacturing methods ; paclitaxel (PTX) ; brain injury ; bovine heparin ; inflammation ; qNMR ; antithrombin ; reference standard ; quantitative NMR ; enoxaparin ; danaparoid sodium ; NMR ; GDNF ; orthogonal multi-analytical methods ; ternary complex ; heparan sulphate ; serglycin ; bovine serum albumin (BSA) ; HSQC ; recombinant expression ; heparin ; heparin oligosaccharides ; functional assay ; BMP antagonists ; intestinal lymphatic absorption ; size exclusion chromatography ; heparin coating ; diagnosis ; bioreactor ; anemia ; proteoglycan ; heparin process ; PCA ; chemometric ; fluorescent probe ; pharmacopeia ; affinity chromatography ; component quantitative analysis ; Fondaparinux sodium ; perylene diimide dyes ; thrombin inhibition ; extended physicochemical characterization ; cisplatin ; glycosaminoglycans ; TGF-? ; chondroitin sulfate ; dalteparin ; sequence and compositional investigations ; molecular weight ; magnetic resonance imaging (MRI) ; industrial ; LC-MS ; iduronic acid conformation ; heparan sulfate ; growth and differentiation factor (GDF) ; assay ; subarachnoid hemorrhage ; thema EDItEUR::P Mathematics and Science::PN Chemistry